Jason Zhang,
Edison Investment Research (5/27/14) "Mesoblast Ltd. intends to initiate a Phase 3 trial of mesenchymal precursor cells in discogenic low back pain later this year, following the successful Phase 2 trial that reported in February. . .now a leading contender in the field, Mesoblast could have five active programs in Phase 3 (two partnered) and four in Phase 2 studies (one partnered) with nine clinical candidates by the end of this year. We expect CEP-41750 to become the leading stem cell therapy for congestive heart failure."
http://www.thelifesciencesreport.com/pub/co/4251
Just on the Professors recent CNBC interview , it appears the Edison analyst shares his confidence and closing comments.
DYOR and do your own thing.
msb the heavyweight, page-25
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
0.010(1.03%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 99.0¢ | 95.5¢ | $5.286M | 5.409M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 91218 | 98.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 63577 | 4 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |